Value based health care in systemic sclerosis: what is the optimal follow-up for patients with systemic sclerosis?
- Conditions
- sclerodermasystemic sclerosis1000381610010761
- Registration Number
- NL-OMON52574
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 250
In order to be eligible to participate in this study, a subject must meet all
the following criteria:
1. Participation in the prospective Haga, HMC or LUMC cohort
2. Clinical diagnosis of SSc
3. Age of >=18 years
4. >= two evaluations in the Care Pathway.
5. Low or intermediate risk for disease progression according to the prediction
model
6. Written informed consent for this study as well as the Leiden CCISS cohort
(Comprehensive Care in Systemic Sclerosis)
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
1. Patients with SSc who are part of ongoing (randomized) trials
2. Patients who have had an autologous stem cell transplantation in the past
five years
3. Patients with SSc who were categorized as high risk for disease progression
according to the predictive model.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1. Primary outcome measures: health care utilization </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary outcome measure: quality of life of SSc patients and patient*s<br /><br>satisfaction and perception of delivery care, and disease progression</p><br>